Clinical Trial Update: Safety and Efficacy Study of MEHD7945A + FOLFIRI Versus Cetuximab + FOLFIRI as Second Line Therapy in Participants With KRAS Wild-Type Metastatic Colorectal Cancer (mCRC) [Phase 2]

View source ↗

Summary

Phase 2 trial comparing MEHD7945A plus FOLFIRI versus cetuximab plus FOLFIRI as second-line therapy for KRAS wild-type metastatic colorectal cancer; the study h…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Cetuximab (cetuximab)
• FOLFIRI (irinotecan, leucovorin, 5-fluorouracil)
• MEHD7945A (MEHD7945A)

Snippet

Sponsor: Genentech, Inc. | Conditions: Colorectal Cancer | Phase 2 | Status: COMPLETED